Search

Your search keyword '"de Vries-Bouwstra, Jeska"' showing total 370 results

Search Constraints

Start Over You searched for: Author "de Vries-Bouwstra, Jeska" Remove constraint Author: "de Vries-Bouwstra, Jeska"
370 results on '"de Vries-Bouwstra, Jeska"'

Search Results

1. The Clinical Aspects of Autoantibodies

4. Does the Impact of COVID‐19 on Patients With Systemic Sclerosis Change Over Time?

5. Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium

7. Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort

9. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

13. Exploring the effects of a combined exercise programme on pain and fatigue outcomes in people with systemic sclerosis: study protocol for a large European multi-centre randomised controlled trial

14. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

16. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

17. The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET

18. Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET

19. Sex-specific difference in cardiac function in patients with systemic sclerosis: association with cardiovascular outcomes

20. Detection of Systemic Sclerosis-associated Interstitial Lung Disease by Exhaled Breath Analysis Using Electronic Nose Technology.

21. Long noncoding RNA H19X is a key mediator of TGF-[beta]-driven fibrosis

23. The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis—Interstitial Lung Disease in the European Scleroderma Trial and Research Database.

24. Screening for ILD in RA: a survey of 1132 patients with RA

25. RA-ILD – new insights into disease burden from an international patient survey

26. Does the impact of COVID‐19 on patients with systemic sclerosis change over time?

28. Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis

29. Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic Sclerosis

32. Step forward in early recognition of systemic sclerosis: data from the Leiden CCISS cohort

33. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database

35. Whole body insulin sensitivity is increased in systemic sclerosis

40. sj-pdf-1-jso-10.1177_23971983231181719 – Supplemental material for The long-term course of the Health Assessment Questionnaire in patients with systemic sclerosis

41. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

44. Mouth opening in systemic sclerosis: Its course over time, determinants and impact on mouth handicap

45. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

47. Exploring the effects of a combined exercise programme on pain and fatigue outcomes in people with systemic sclerosis: Study protocol for a large European multi-centre randomised controlled trial.

48. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

49. Clinical characteristics of juvenile onset systemic sclerosis patients from the juvenile scleroderma inception cohort compared to adult age juvenile-onset patients from EUSTAR. Are these differences suggesting risk for mortality?

50. Reply

Catalog

Books, media, physical & digital resources